Aequus Historical Balance Sheet

AQS Stock  CAD 0.01  0.01  100.00%   
Trend analysis of Aequus Pharmaceuticals balance sheet accounts such as Total Current Liabilities of 5 M, Net Tangible Assets of 1.7 M or Property Plant And Equipment Net of 683.1 K provides information on Aequus Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Aequus Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Aequus Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Aequus Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Aequus Pharmaceuticals is a good buy for the upcoming year.

Aequus Pharmaceuticals Inventory

129,933

  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aequus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About Aequus Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Aequus Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Aequus Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Aequus Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Aequus currently owns. An asset can also be divided into two categories, current and non-current.

Aequus Pharmaceuticals Balance Sheet Chart

At this time, Aequus Pharmaceuticals' Property Plant Equipment is fairly stable compared to the past year. Non Current Liabilities Total is likely to climb to about 774.1 K in 2024, despite the fact that Total Stockholder Equity is likely to grow to (4.1 M).

Total Assets

Total assets refers to the total amount of Aequus Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Aequus Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Aequus Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Aequus Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Property Plant And Equipment Net

The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.

Accounts Payable

An accounting item on the balance sheet that represents Aequus Pharmaceuticals obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Aequus Pharmaceuticals are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Total Current Assets

The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.
Most accounts from Aequus Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Aequus Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aequus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
At this time, Aequus Pharmaceuticals' Property Plant Equipment is fairly stable compared to the past year. Non Current Liabilities Total is likely to climb to about 774.1 K in 2024, despite the fact that Total Stockholder Equity is likely to grow to (4.1 M).
 2021 2022 2023 2024 (projected)
Total Current Liabilities2.5M2.4M4.8M5.0M
Total Assets4.3M1.7M1.1M1.0M

Aequus Pharmaceuticals balance sheet Correlations

0.050.510.49-0.01-0.36-0.340.420.840.410.840.680.350.240.560.690.10.940.420.19-0.010.290.32-0.19-0.250.42
0.05-0.760.50.770.78-0.730.05-0.120.36-0.11-0.10.690.720.31-0.360.92-0.070.590.480.16-0.48-0.5-0.65-0.55-0.63
0.51-0.760.02-0.79-0.940.530.280.6-0.040.580.33-0.49-0.530.010.56-0.80.56-0.38-0.56-0.170.450.460.620.490.84
0.490.50.020.22-0.06-0.280.130.550.070.570.010.350.220.42-0.220.330.510.24-0.070.26-0.3-0.35-0.18-0.14-0.08
-0.010.77-0.790.220.77-0.84-0.23-0.240.28-0.230.130.80.690.5-0.220.91-0.10.730.820.51-0.34-0.33-0.88-0.78-0.75
-0.360.78-0.94-0.060.77-0.67-0.26-0.560.2-0.55-0.080.590.650.08-0.30.85-0.460.540.64-0.01-0.31-0.33-0.67-0.62-0.75
-0.34-0.730.53-0.28-0.84-0.670.050.08-0.60.07-0.51-0.94-0.79-0.7-0.2-0.85-0.16-0.97-0.77-0.280.10.150.790.890.53
0.420.050.280.13-0.23-0.260.050.340.550.34-0.12-0.17-0.070.110.17-0.030.25-0.05-0.24-0.22-0.12-0.130.340.280.06
0.84-0.120.60.55-0.24-0.560.080.34-0.091.00.33-0.03-0.10.180.43-0.110.95-0.04-0.03-0.130.250.330.00.080.53
0.410.36-0.040.070.280.2-0.60.55-0.09-0.090.360.490.460.630.350.330.080.640.170.13-0.19-0.27-0.1-0.3-0.18
0.84-0.110.580.57-0.23-0.550.070.341.0-0.090.33-0.02-0.090.190.42-0.10.95-0.03-0.03-0.130.240.32-0.010.070.52
0.68-0.10.330.010.13-0.08-0.51-0.120.330.360.330.510.370.550.870.080.610.630.440.030.640.62-0.39-0.610.31
0.350.69-0.490.350.80.59-0.94-0.17-0.030.49-0.020.510.790.630.150.780.20.960.70.38-0.1-0.13-0.8-0.84-0.42
0.240.72-0.530.220.690.65-0.79-0.07-0.10.46-0.090.370.790.460.090.780.10.750.620.22-0.12-0.1-0.76-0.7-0.26
0.560.310.010.420.50.08-0.70.110.180.630.190.550.630.460.30.380.390.710.350.54-0.11-0.18-0.36-0.54-0.16
0.69-0.360.56-0.22-0.22-0.3-0.20.170.430.350.420.870.150.090.3-0.180.620.340.24-0.310.680.7-0.06-0.260.53
0.10.92-0.80.330.910.85-0.85-0.03-0.110.33-0.10.080.780.780.38-0.180.00.720.770.18-0.33-0.32-0.84-0.74-0.68
0.94-0.070.560.51-0.1-0.46-0.160.250.950.080.950.610.20.10.390.620.00.230.15-0.060.370.44-0.18-0.170.51
0.420.59-0.380.240.730.54-0.97-0.05-0.040.64-0.030.630.960.750.710.340.720.230.710.28-0.01-0.06-0.71-0.85-0.39
0.190.48-0.56-0.070.820.64-0.77-0.24-0.030.17-0.030.440.70.620.350.240.770.150.710.170.090.17-0.92-0.83-0.46
-0.010.16-0.170.260.51-0.01-0.28-0.22-0.130.13-0.130.030.380.220.54-0.310.18-0.060.280.17-0.29-0.31-0.32-0.25-0.28
0.29-0.480.45-0.3-0.34-0.310.1-0.120.25-0.190.240.64-0.1-0.12-0.110.68-0.330.37-0.010.09-0.290.97-0.04-0.270.44
0.32-0.50.46-0.35-0.33-0.330.15-0.130.33-0.270.320.62-0.13-0.1-0.180.7-0.320.44-0.060.17-0.310.97-0.09-0.210.52
-0.19-0.650.62-0.18-0.88-0.670.790.340.0-0.1-0.01-0.39-0.8-0.76-0.36-0.06-0.84-0.18-0.71-0.92-0.32-0.04-0.090.870.46
-0.25-0.550.49-0.14-0.78-0.620.890.280.08-0.30.07-0.61-0.84-0.7-0.54-0.26-0.74-0.17-0.85-0.83-0.25-0.27-0.210.870.47
0.42-0.630.84-0.08-0.75-0.750.530.060.53-0.180.520.31-0.42-0.26-0.160.53-0.680.51-0.39-0.46-0.280.440.520.460.47
Click cells to compare fundamentals

Aequus Pharmaceuticals Account Relationship Matchups

Aequus Pharmaceuticals balance sheet Accounts

201920202021202220232024 (projected)
Total Assets1.7M3.1M4.3M1.7M1.1M1.0M
Total Current Liabilities476.0K384.3K2.5M2.4M4.8M5.0M
Total Stockholder Equity(877.1K)574.0K1.8M(1.4M)(4.3M)(4.1M)
Net Tangible Assets934.2K(961.9K)574.0K1.8M1.6M1.7M
Property Plant And Equipment Net480.1K366.3K242.3K788.8K650.6K683.1K
Net Debt1.7M604.7K(211.3K)533.1K4.9M5.1M
Retained Earnings(23.7M)(24.7M)(26.5M)(29.7M)(32.7M)(31.1M)
Accounts Payable249.5K160.9K157.1K88.5K274.2K286.1K
Cash484.5K1.7M2.4M249.8K170.2K161.7K
Non Current Assets Total564.9K366.3K755.1K788.8K650.6K710.7K
Cash And Short Term Investments484.5K1.7M2.4M294.7K215.0K204.3K
Net Receivables556.3K779.5K941.1K310.1K31.7K30.1K
Common Stock Shares Outstanding80.4M93.2M128.8M132.6M152.5M83.9M
Liabilities And Stockholders Equity1.7M3.1M4.3M1.7M1.1M1.0M
Inventory5.4K123.3K139.8K93.8K123.7K129.9K
Other Current Assets61.5K146.7K120.5K204.1K65.1K113.5K
Other Stockholder Equity3.7M4.1M4.3M(1.0)(1.15)(1.09)
Total Liab2.5M2.6M2.6M3.1M5.4M5.6M
Total Current Assets1.1M2.8M3.6M902.7K435.6K413.8K
Common Stock18.9M19.1M21.2M24.0M27.6M17.2M
Property Plant Equipment14.1K480.1K366.3K242.3K278.6K292.6K
Other Current Liab83K76.3K221.7K2.2M42.1K40.0K
Non Currrent Assets Other19.0K761.5K512.8K(1.0)(1.15)(1.09)
Non Current Liabilities Total2.1M2.2M102.0K693.8K583.6K774.1K
Net Invested Capital888.3K2.6M3.7M620.0K76.2K72.3K
Net Working Capital631.7K2.4M1.1M(1.5M)(4.4M)(4.1M)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Aequus Stock Analysis

When running Aequus Pharmaceuticals' price analysis, check to measure Aequus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aequus Pharmaceuticals is operating at the current time. Most of Aequus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aequus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aequus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aequus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.